Metabolically healthy obesity: the low-hanging fruit in obesity treatment?

The Lancet Diabetes and Endocrinology

Volumn 6, Issue 3, 2018, Pages 249-258

  Stefan, Norbert ^a,b,c   Häring, Hans Ulrich ^a,b,c   Schulze, Matthias B ^c,d  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Institute of Diabetes Research and Metabolic Diseases   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALL CAUSE MORTALITY; BODY FAT; BODY WEIGHT LOSS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; DOCTOR PATIENT RELATION; FAT MASS; HEALTHY LIFESTYLE; HIGH RISK POPULATION; HUMAN; INTERPERSONAL COMMUNICATION; LIFESTYLE MODIFICATION; MEDITERRANEAN DIET; METABOLIC PARAMETERS; MOTIVATION; OBESITY; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; BODY MASS; BODY WEIGHT; LIFESTYLE; METABOLICALLY BENIGN OBESITY;

BODY MASS INDEX; BODY WEIGHT; HUMANS; LIFE STYLE; OBESITY, METABOLICALLY BENIGN;

EID: 85029420029     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30292-9     Document Type: Review

References (70)

1. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387 (2016), 1377–1396.
2. National Center for Health Statistics (US). Health, United States, 2015: with special feature on racial and ethnic health disparities, 2016, National Center for Health Statistics (US), Hyattsville, MD.
3. Heymsfield, SB, Wadden, TA, Mechanisms, pathophysiology, and management of obesity. N Engl J Med 376 (2017), 254–266.
4. American Medical Association House of Delegates. Relevant AMA policy. http://www.npr.org/documents/2013/jun/ama-resolution-obesity.pdf (accessed Sept 4, 2017).
5. Flegal, KM, Kit, BK, Orpana, H, Graubard, BI, Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309 (2013), 71–82.
6. Hughes, V, The big fat truth. Nature 497 (2013), 428–430.
7. Ahima, RS, Lazar, MA, Physiology. The health risk of obesity—better metrics imperative. Science 341 (2013), 856–858.
8. Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 388 (2016), 776–786.
9. Eckel, RH, Jakicic, JM, Ard, JD, et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129 (2014), S76–S99.
10. American Diabetes Association. Foundations of care and comprehensive medical evaluation. Diabetes Care 39:suppl 1 (2016), S23–S35.
11. American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Obesity Expert Panel, 2013. Executive summary: guidelines (2013) for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Obesity Society published by the Obesity Society and American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Based on a systematic review from the The Obesity Expert Panel, 2013. Obesity (Silver Spring) 22:suppl 2 (2014), S5–S39.
12. Jensen, MD, Ryan, DH, Apovian, CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63 (2014), 2985–3023.
13. Pi-Sunyer, X, Blackburn, G, Brancati, FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30 (2007), 1374–1383.
14. Wing, RR, Bolin, P, Brancati, FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 369 (2013), 145–154.
15. Knowler, WC, Fowler, SE, Hamman, RF, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 374 (2009), 1677–1686.
16. Gregg, EW, Jakicic, JM, Blackburn, G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 4 (2016), 913–921.
17. Knowler, WC, Barrett-Connor, E, Fowler, SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2001), 393–403.
18. Tuomilehto, J, Lindstrom, J, Eriksson, JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001), 1343–1350.
19. Rejeski, WJ, Ip, EH, Bertoni, AG, et al. Lifestyle change and mobility in obese adults with type 2 diabetes. N Engl J Med 366 (2012), 1209–1217.
20. The Trials of Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med 157 (1997), 657–667.
21. Wing, RR, Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med 170 (2010), 1566–1575.
22. Eckel, N, Meidtner, K, Kalle-Uhlmann, T, Stefan, N, Schulze, MB, Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol 23 (2016), 956–966.
23. Grundy, SM, Cleeman, JI, Daniels, SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005), 2735–2752.
24. Williams, MV, Davis, T, Parker, RM, Weiss, BD, The role of health literacy in patient-physician communication. Fam Med 34 (2002), 383–389.
25. Temple, NJ, Fraser, J, Food labels: a critical assessment. Nutrition 30 (2014), 257–260.
26. Lassale, C, Tzoulaki, I, Moons, KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J, 2017 published online Aug 14. DOI:10.1093/eurheartj/ehx448.
27. Lotta, LA, Gulati, P, Day, FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet 49 (2017), 17–26.
28. Stefan, N, Häring, H-U, Hu, FB, Schulze, MB, Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol 1 (2013), 152–162.
29. Wildman, RP, Muntner, P, Reynolds, K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med 168 (2008), 1617–1624.
30. Stefan, N, Kantartzis, K, Machann, J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168 (2008), 1609–1616.
31. McLaughlin, T, Abbasi, F, Lamendola, C, Reaven, G, Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 167 (2007), 642–648.
32. Karelis, AD, St-Pierre, DH, Conus, F, Rabasa-Lhoret, R, Poehlman, ET, Metabolic and body composition factors in subgroups of obesity: what do we know?. J Clin Endocrinol Metab 89 (2004), 2569–2575.
33. Meigs, JB, Wilson, PW, Fox, CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91 (2006), 2906–2912.
34. Karelis, AD, Rabasa-Lhoret, R, Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. Diabetes Metab 34 (2008), 183–184.
35. Blüher, M, Are metabolically healthy obese individuals really healthy?. Eur J Endocrinol 171 (2014), 209–219.
36. Samocha-Bonet, D, Dixit, VD, Kahn, CR, et al. Metabolically healthy and unhealthy obese–the 2013 Stock Conference report. Obes Rev 15 (2014), 697–708.
37. Lotta, LA, Abbasi, A, Sharp, SJ, et al. Definitions of metabolic health and risk of future type 2 diabetes in BMI categories: a systematic review and network meta-analysis. Diabetes Care 38 (2015), 2177–2187.
38. Mathew, H, Farr, OM, Mantzoros, CS, Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism 65 (2016), 73–80.
39. Kramer, CK, Zinman, B, Retnakaran, R, Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med 159 (2013), 758–769.
40. Appleton, SL, Seaborn, CJ, Visvanathan, R, et al. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes Care 36 (2013), 2388–2394.
41. Hamer, M, Bell, JA, Sabia, S, Batty, GD, Kivimäki, M, Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Ageing. Eur J Endocrinol 173 (2015), 703–708.
42. Phillips, CM, Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann N Y Acad Sci 1391 (2017), 85–100.
43. Bell, JA, Kivimaki, M, Hamer, M, Metabolically healthy obesity and risk of incident type 2 diabetes: a meta-analysis of prospective cohort studies. Obes Rev 15 (2014), 504–515.
44. Sjostrom, L, Peltonen, M, Jacobson, P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 307 (2012), 56–65.
45. Sjostrom, L, Narbro, K, Sjostrom, CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 357 (2007), 741–752.
46. Sjostrom, L, Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med 273 (2013), 219–234.
47. Eckel, RH, Alberti, KG, Grundy, SM, Zimmet, PZ, The metabolic syndrome. Lancet 375 (2010), 181–183.
48. Magkos, F, Fraterrigo, G, Yoshino, J, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab 23 (2016), 591–601.
49. Shin, MJ, Hyun, YJ, Kim, OY, Kim, JY, Jang, Y, Lee, JH, Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond) 30 (2006), 1529–1534.
50. Karelis, AD, Messier, V, Brochu, M, Rabasa-Lhoret, R, Metabolically healthy but obese women: effect of an energy-restricted diet. Diabetologia 51 (2008), 1752–1754.
51. Janiszewski, PM, Ross, R, Effects of weight loss among metabolically healthy obese men and women. Diabetes Care 33 (2010), 1957–1959.
52. Kantartzis, K, Machann, J, Schick, F, et al. Effects of a lifestyle intervention in metabolically benign and malign obesity. Diabetologia 54 (2011), 864–868.
53. Ruiz, JR, Ortega, FB, Labayen, I, A weight loss diet intervention has a similar beneficial effect on both metabolically abnormal obese and metabolically healthy but obese premenopausal women. Ann Nutr Metab 62 (2013), 223–230.
54. Dalzill, C, Nigam, A, Juneau, M, et al. Intensive lifestyle intervention improves cardiometabolic and exercise parameters in metabolically healthy obese and metabolically unhealthy obese individuals. Can J Cardiol 30 (2014), 434–440.
55. Micha, R, Peñalvo, JL, Cudhea, F, Imamura, F, Rehm, CD, Mozaffarian, D, Association between dietary factors and mortality from heart disease, stroke, and type 2 diabetes in the United States. JAMA 317 (2017), 912–924.
56. Appel, LJ, Moore, TJ, Obarzanek, E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336 (1997), 1117–1124.
57. Appel, LJ, Sacks, FM, Carey, VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial. JAMA 294 (2005), 2455–2464.
58. Estruch, R, Ros, E, Salas-Salvadó, J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 368 (2013), 1279–1290.
59. Estruch, R, Martínez-González, MA, et al. Effect of a high-fat Mediterranean diet on bodyweight and waist circumference: a prespecified secondary outcomes analysis of the PREDIMED randomised controlled trial. Lancet Diabetes Endocrinol 4 (2016), 666–676.
60. Salas-Salvadó, J, Fernández-Ballart, J, Ros, E, et al. Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: one-year results of the PREDIMED randomized trial. Arch Intern Med 168 (2008), 2449–2458.
61. The Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition (CIBERobn). http://www.predimedplus.com/en/project (accessed on May 31, 2017).
62. Howard, BV, Van Horn, L, Hsia, J, et al. Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 295 (2006), 655–666.
63. Bray, GA, Siri-Tarino, PW, The role of macronutrient content in the diet for weight management. Endocrinol Metab Clin North Am 45 (2016), 581–604.
64. Nordmann, AJ, Nordmann, A, Briel, M, et al. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006), 285–293.
65. Johnston, BC, Kanters, S, Bandayrel, K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 312 (2014), 923–933.
66. Wycherley, TP, Moran, LJ, Clifton, PM, Noakes, M, Brinkworth, GD, Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr 96 (2012), 1281–1298.
67. Guo, F, Garvey, WT, Cardiometabolic Disease Staging predicts effectiveness of weight loss therapy to prevent type 2 diabetes: pooled results from phase III clinical trials assessing phentermine/topiramate extended release. Diabetes Care 40 (2017), 856–862.
68. Karelis, AD, Metabolically healthy but obese individuals. Lancet 372 (2008), 1281–1283.
69. Stefan, N, Schick, F, Häring, H-U, Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab 26 (2017), 292–300.
70. Snook, KR, Hansen, AR, Duke, CH, Finch, KC, Hackney, AA, Zhang, J, Change in percentages of adults with overweight or obesity trying to lose weight, 1988–2014. JAMA 317 (2017), 971–973.